Helpline: 09 820 5157

Vision Appeal - Research Fund

Our research commitment

Coeliac NZ is committed to improve the understanding and treatment of coeliac disease, and to support research towards finding a cure. As we do not receive any government funding our work depends on the generosity of our members and supporters. Every dollar contributed makes a difference so please consider making a tax deductible donation to our dedicated Coeliac NZ research fund at or using the donation button below.

We can’t do it alone – your help is needed.

And this year one lucky CNZ member who donates to our dedicated research fund before the 27th of February 2019 will receive a Breville Bakers Oven (valued at $249.95). The prize will be drawn on the 28th February – no cash equivalent option available.

See for more details about the specialised gluten free programme on the Breville Bakers Oven


ReSet CeD Study – phase 2 test Nexvax2®.

CNZ are encouraging its members to participate in a major international research study to test an experimental treatment that aims to protect against the effects of inadvertent gluten exposure. People with medically-confirmed coeliac disease and following a gluten-free diet are being invited to participate in the study to test Nexvax2®. New Zealand volunteers, study sites and scientists have played a central role in the history of Nexvax2®, which is being developed by ImmusanT Inc., a biotech company based in Cambridge, Massachusetts USA.

The recently initiated Phase-2 study is designed to show that regular Nexvax2® injections protect against the effects of “one-off” gluten exposure in patients doing their best to maintain a strict gluten-free diet.The trial is enrolling patients who have been on a gluten-free diet for a year and have had prior blood tests, and a stomach or duodenal biopsy, positive for celiac disease. The effectiveness of Nexvax2® is being compared with that of a placebo (or sham) treatment, and the study will take approximately 6 months for a patient to complete

The Micro-gluten Challenge Study

CNZ will be contributing to a trans-Tasman study to evaluate whether the fixed threshold of less than 20 parts per million of gluten adopted by the Codex Alimentarius and FDA safe for the treatment of coeliac disease is safe compared with the Food Standards Australia New Zealand (FSANZ) standard of“no detectable gluten” or other limit.

Quality of Life study

A Christchurch research study conducted by University of Canterbury, Masters student Malena Penney into immune-related disorders, including coeliac disease and food allergies seeks to investigate the impact these health issues have on a child’s health-related quality of life. The study aims to evaluate how parental anxiety and the burden of managing a restricted diet impacts the child. The findings from this project will help CNZ develop new resources for coeliac children and their families in the future.


For coeliacs maintaining a strict gluten free diet is a medical necessity for life, but it is not a cure.

Thanks for making Coeliac New Zealand your charity of choice, and helping to strengthen our research efforts towards improving the lives of all coeliacs.


Make A Donation